본문 바로가기

전체 글

 (819)
Chronic Kidney Disease Market Outlook In 2017, the total prevalent population of Chronic Kidney Disease (CKD) was found to be 122,704,658 in the seven major markets. The prevalent population of Chronic Kidney Disease in the United States was 35,288,932 while Japan had 21,183,442 prevalent cases of CKD in 2017. The market size of Chronic Kidney Disease (CKD) in the 7MM is estimated to be USD 16,897.5 Million by 2030. Advances and fut..
Frontotemporal Dementia Market outlook As per the NORD, Frontotemporal degeneration affects around 50,000-60,000 people in the United States. As per the DelveInsight, the total number of Frontotemporal prevalent cases in the seven major markets was found to be 76,499 in the year 2017. The Frontotemporal Dementia market is expected to increase with a CAGR of 21.41% for the seven major markets [i.e. the USA, EU5 ( the UK, Germany, Fran..
Complement 3 Glomerulopathy (C3G) Market Forecast The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in 2017 was 8,175 in the seven major markets. In 2017, the United States accounted for the highest diagnosed prevalent cases of C3G with 3,967 cases. The market size of Complement 3 Glomerulopathy (C3G) in 7MM was USD 40.6 Million in 2017, which is expected to increase during the study period 2017-2030. The key players..
Acromegaly Market outlook The total prevalent cases of Acromegaly in 2017 was 64,508 in seven major markets. In 2017, the prevalent population of Acromegaly in the United States was found to be 28,671 cases while Japan has around 10,690 prevalent cases. The EU5 countries (i.e. the UK, Spain, Germany, France, and Italy) occupied nearly 38.98% of the patient pool amongst 7MM in 2017. The market size of Acromegaly was estim..
Familial Chylomicronemia Syndrome Market Insight The total Familial chylomicronemia syndrome prevalent population in the 7MM (the US, EU5 (the UK, Germany, France, Spain, and Italy) and Japan) was assessed to be 5,801 in 2017. The current Familial Chylomicronemia Syndrome market is mainly dominated by traditional TG-lowering agents, and as per DelveInsight analysis, the market worth was estimated to be USD 1.0 million in 2017. Some of the lead..
Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight The total diagnosed prevalent population of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM was 533,263 in 2017. The diagnosed prevalent population of NMIBC in Japan in 2017 was 74,691. The EU5 countries ( i.e the Uk, Spain, France, Germany, Italy) occupied approximately 45.90% of the patient pool amongst seven major markets. The market size of Non-Muscle Invasive Bladder Cancer (NMIBC) in 7MM..
Internet Of Things in healthcare sector Internet Of Things is the next big entity in the healthcare system, set to completely revolutionize the healthcare delivery and design system in the coming future years. The main focus of IoT is to prevent disease rather than curing it. IoT has a promising future, since the technology is in the initial phase right now, many big players whether investors or manufacturers to fulfill the user’s and..
Exocrine Pancreatic Insufficiency Market Insight The prevalence of causative Indications of Exocrine Pancreatic Insufficiency observed in Type II Diabetes Mellitus in 2017 was 67,892,836 in the seven major markets. Among the 7MM, the United States has the highest percentage of prevalent diagnosed and treated patients of Exocrine Pancreatic Insufficiency (EPI). The market size of Exocrine Pancreatic Insufficiency in the 7MM was found to be USD ..

티스토리툴바